14,232 Stryker Corporation $SYK Shares Sold by Peterson Wealth Services

Peterson Wealth Services lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 99.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 109 shares of the medical technology company’s stock after selling 14,232 shares during the period. Peterson Wealth Services’ holdings in Stryker were worth $30,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. State Street Corp grew its stake in Stryker by 1.2% in the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after purchasing an additional 183,400 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Stryker during the 2nd quarter worth approximately $1,404,284,000. Royal Bank of Canada raised its stake in shares of Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after buying an additional 481,175 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE:SYK opened at $301.59 on Wednesday. The stock’s 50 day moving average price is $294.70 and its two-hundred day moving average price is $325.45. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm earned $3.13 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%.

Insider Buying and Selling

In other Stryker news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronda Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on SYK. BTIG Research decreased their target price on shares of Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target on the stock. Stifel Nicolaus cut their price target on shares of Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Finally, TD Cowen decreased their price objective on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.